Ratings Surperformance

Trader
Investor
Global
Quality
ESG MSCI
AAA

Ratings ESG MSCI

Ratings Novartis AG: Strengths and Weaknesses

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • According to MSCI, the company's ESG score for its industry is good.
Highlights: Novartis AG
  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Over the past four months, analysts' average price target has been revised upwards significantly.
  • The opinion of analysts covering the stock has improved over the past four months.
Weaknesses: Novartis AG
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • Over the past twelve months, analysts' opinions have been revised negatively.

Rating Financials

Novartis AG SectorSwitzerland
Fundamentals
Growth
Revenue growth
EPS growth
FCF growth
Profitability
EBITDA Margin
EBIT Margin
Net Margin
Capital Efficiency
ROA
ROCE
ROE
Financial Health
Gearing
Leverage
Capital Intensity
Balance sheet growth
Long Term balance sheet growth
Long term revenue growth
Long term EPS growth
More ratings

Rating Valuation

Novartis AG SectorSwitzerland
Global Valuation
Enterprise value
EV/Revenue
EV/EBITDA
EV/FCF
Equity Valuation
P/E
PBR
Dividend Yield
EV/EBIT
CAPEX/Revenue
More ratings

Rating Consensus

Novartis AG SectorSwitzerland
Consensus
Analysts' buy/sell recommendations
Analysts' recommendations evolution (1 year)
Analysts' recommendations evolution (4 months)
Analysts' target price
Analysts' target price evolution (1 year)
Analysts' target price evolution (4 months)
Analysts' recommendations evolution (7 days)
Target Price evolution (7 days)
More ratings

Rating Business Predictability

Novartis AG SectorSwitzerland
Visibility
Analysts' coverage
Financial estimates divergence
Analysts' recommendations divergence
Analysts' Target price divergence
Surprise rates

Rating Revisions

Novartis AG SectorSwitzerland
Financial revisions
Revenue revisions (1 year)
Revenue revisions (4 months)
EPS revisions (1 year)
EPS revisions (4 months)
EPS revisions (7 days)
Revenue revisions (7 days)
More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
259B
AAA
951B
A
516B
BBB
402B
AA
346B
AA
282B
A
249B
A
221B
A
175B
A
149B
AAA
Average 355.01B
AA
Weighted average by Cap.
AA
See all sector ratings